https://www.ncbi.nlm...pubmed/27926589
Dystonia in Methylphenidate Withdrawal: A Case Report.
Few studies have described movement disorders as withdrawal symptoms during psychostimulant detoxification. Although dystonia has been reported as an uncommon adverse effect of methylphenidate treatment, it has not been described in the context of methylphenidate withdrawal. We report a case of dystonia as the main withdrawal symptom in a methylphenidate-dependent adult participating in an inpatient methylphenidate detoxification program. Although movement disorders such as dystonia are very rare adverse effects of methylphenidate withdrawal, practitioners need to be alert to this risk in order to initiate appropriate treatment.
https://www.ncbi.nlm...les/PMC5896529/
Stimulant (Ritalin) Withdrawal in a Child with Autism Spectrum Disorder and ADHD - A Case Report
Full article
https://www.ncbi.nlm...pubmed/26132330
Painful Muscle Cramps Possibly Associated with Withdrawal from Methylphenidate.
No summary available.
https://www.ncbi.nlm...pubmed/20832433
Withdrawal from methylphenidate increases neural reactivity of dorsal midbrain.
Our results provide new findings about the influence of MP treatment in adult rats, showing that, after a sudden MP treatment-break, increased anxiety, associated with the neural sensitization of anxiety-related regions, ensues.
https://www.ncbi.nlm...pubmed/25323763
An N-of-1 trial as an individualized withdrawal treatment approach to psychological methylphenidate dependence.
A partial text is available a this site.
https://www.karger.c...Abstract/365094
https://www.ncbi.nlm...pubmed/15127013
Stuttering priapism associated with withdrawal from sustained-release methylphenidate.
Stuttering priapism is intermittent, prolonged, painful, pathologic erections with intervening periods of detumescence. An adolescent had stuttering priapism associated with withdrawal from sustained-release methylphenidate. To our knowledge, this is the first such report of stuttering priapism associated with stimulant drugs for treatment of attention deficit hyperactivity disorder.
https://www.ncbi.nlm...pubmed/16139732
Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate.
Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder of childhood, which is frequently treated with methylphenidate. The short-term response to treatment with methylphenidate is a substantial decrease in dopamine transporter density, with improvement in neuropsychological tests. In this study, single-photon emission computed tomography was used to investigate possible long-term alterations in the cerebral dopamine system after cessation of treatment with methylphenidate in five children with ADHD. Three months after initiation of treatment with methylphenidate, a reduction of the dopamine transporter in the striatal system was observed. Methylphenidate was administered for a period of 9 to 20 months. Follow-up with single-photon emission computed tomography after withdrawal of methylphenidate medication disclosed an increase of dopamine transporter activity comparable with pretreatment values. The observed upregulation of dopamine transporter activity might support the assumption that methylphenidate does not lead to permanent damage of the nigrostriatal dopaminergic pathways.
https://www.ncbi.nlm...pubmed/10103294
Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder.
Abrupt withdrawal of stimulant medication in children receiving long-term maintenance therapy does not appear to result in worsening of tic frequency or severity. Nevertheless, these findings do not preclude the possibility of drug withdrawal reactions in susceptible individuals.
http://jnm.snmjourna...43/12/1624.long
Effects of Methylphenidate Discontinuation on Cerebral Blood Flow in Prepubescent Boys with Attention Deficit Hyperactivity Disorder
Brief discontinuation of MPH treatment is associated with increased motor and anterior cingulate cortical activity. Our findings suggest that MPH treatment modulates motor and anterior cingulate cortical activity directly or indirectly. Alternatively, our findings may be related to MPH withdrawal. These data provide novel information on the potential mechanisms of the therapeutic action of MPH. Furthermore, they are clinically relevant to the commonly occurring brief interruptions in MPH treatment.
https://www.ncbi.nlm...cles/PMC181133/
The clinical picture of stimulant intoxication produces a wide array of symptoms including schizophrenic symptoms, manic-like states, psychoses, depressions (especially during withdrawal), and various types of anxiety conditions including panic states.
https://www.liebertp...9/cap.2019.0147
Methylphenidate on Strengths and Difficulties, Quality of Life and Parenting Stress
Ninety-four children and adolescents aged 8 to 18 years who had used methylphenidate for over 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg extended release methylphenidate) or to gradual withdrawal over 3 to 4 weeks placebo.
https://ajp.psychiat...p.2019.18111296
Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study
Ninety-four children and adolescents (ages 8–18 years) who had been treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo.
https://www.aap.org/...te-Ritalin.aspx
Discontinuing Methylphenidate and Possible Withdrawal Adverse Effects
⦁ For most patients, particularly those receiving extended-release (ER) preparations at recommended dosages, methylphenidate can be discontinued abruptly.
⦁ To minimize withdrawal adverse effects, particularly for patients receiving high doses, staggered discontinuation of methylphenidate over a few days to weeks is recommended.
⦁ Potential withdrawal adverse effects include anxiety, irritability, insomnia, and increased blood pressure.